Clinical Trials Logo

SMARCB1 Negative clinical trials

View clinical trials related to SMARCB1 Negative.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT03587662 Active, not recruiting - Clinical trials for Metastatic Renal Cell Carcinoma

Ixazomib, Gemcitabine, and Doxorubicin in Treating Patients With Locally Advanced or Metastatic Kidney Cancer

Start date: August 17, 2018
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well ixazomib, gemcitabine, and doxorubicin work in treating patients with kidney cancer that has spread to other places in the body (locally advanced or metastatic). Ixazomib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as gemcitabine and doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving ixazomib, gemcitabine, and doxorubicin may work better in treating patients with kidney cancer.